223 related articles for article (PubMed ID: 32395289)
1. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.
Matsubara T; Takamori S; Haratake N; Toyozawa R; Miura N; Shimokawa M; Yamaguchi M; Seto T; Takenoyama M
J Thorac Dis; 2020 Apr; 12(4):1520-1528. PubMed ID: 32395289
[TBL] [Abstract][Full Text] [Related]
2. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
[TBL] [Abstract][Full Text] [Related]
3. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
4. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer.
Erciyestepe M; Selvi O; Dinç Sonuşen Ş; Öztürk AE; Dinç G; Güneş TK; Aydın O; Yaşar N; Balkaya Aykut G; Vatansever S
Med Princ Pract; 2024; 33(2):122-132. PubMed ID: 38091965
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer.
Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
Lung Cancer (Auckl); 2017; 8():249-257. PubMed ID: 29263709
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
Yamaguchi O; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Hashimoto K; Kobayashi K; Kagamu H
Oncology; 2024; 102(3):271-282. PubMed ID: 37725914
[TBL] [Abstract][Full Text] [Related]
11. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer.
Pirlog CF; Cotan HT; Parosanu A; Orlov Slavu C; Popa AM; Iaciu C; Olaru M; Oprita AV; Nita I; Nitipir C
Cureus; 2022 Jul; 14(7):e26843. PubMed ID: 35974841
[TBL] [Abstract][Full Text] [Related]
13. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
14. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors.
Zhang Y; Jin J; Tang M; Li P; Zhou LN; Du YP; Chen MB
Biomed Res Int; 2022; 2022():6743126. PubMed ID: 35707390
[TBL] [Abstract][Full Text] [Related]
16. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Fornarini G; Rebuzzi SE; Banna GL; Calabrò F; Scandurra G; De Giorgi U; Masini C; Baldessari C; Naglieri E; Caserta C; Manacorda S; Maruzzo M; Milella M; Buttigliero C; Tambaro R; Ermacora P; Morelli F; Nolè F; Astolfi C; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100118. PubMed ID: 33984678
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers.
Tang Y; Li G; Wu S; Tang L; Zhang N; Liu J; Zhang S; Yao L
Oncol Lett; 2018 Apr; 15(4):4988-4996. PubMed ID: 29552135
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy.
Fang Q; Yu J; Li W; Luo J; Deng Q; Chen B; He Y; Zhang J; Zhou C
Clin Exp Pharmacol Physiol; 2023 Feb; 50(2):178-190. PubMed ID: 36419356
[TBL] [Abstract][Full Text] [Related]
20. Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer.
Takamizawa Y; Shida D; Boku N; Nakamura Y; Ahiko Y; Yoshida T; Tanabe T; Takashima A; Kanemitsu Y
BMC Cancer; 2020 Nov; 20(1):1092. PubMed ID: 33176752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
